Shares of San Diego-based Cytori Therapeutics $CYTX bumped higher Monday morning on some mixed data for its regenerative cell therapy aimed at erectile dysfunction among a small group of patients with treatment-resistant cases of ED following radical prostatectomy.
There was a hit and a miss on a couple of key endpoints. Researchers say that the microcap biotech’s therapy scored a positive p value on the International Index of Erectile Function-5 (IIEF-5), but showed no change for the Erection Hardness Score (EHS) used by patients.
Once they weeded out incontinent patients, though, Cytori claimed the win in the remaining subset.
It’s early days for this therapy. The study was an open label Phase I at Cytori, which has a minuscule $10 million market cap. The once high-flying biotech has been hit with a series of setbacks, including a clinical hold back in 2014.
Shares surged about 10% on the results. Cytori is also running a small study for urinary incontinence among post-surgery patients.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,500+ biopharma pros who read Endpoints News by email every day.Free Subscription